Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
See Latest ArticlesRecurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes
Journal of Infection, 06/10/09
Johnson S et al. - Current guidelines recommend that the first recurrent episode be treated with the same agent (i.e., metronidazole or vancomycin) used for the index episode. A reasonable strategy for managing a subsequent episode involves tapering followed by pulsed doses of vancomycin. Other potentially effective strategies for recurrent CDI include vancomycin with adjunctive treatments, such as Saccharomyces boulardii, rifaximin “chaser” therapy after vancomycin, nitazoxanide, fecal transplantation, and intravenous immunoglobulin. New treatment agents that are active against C. difficile, but spare critical components of the normal flora, may decrease the incidence of recurrent CDI.
Related Articles
Toxigenic Clostridium difficile colonization in children
Journal of Pediatric Infectious Diseases, 10/30/09
Relevance Score: 68%
Molecular Epidemiology of Clostridium difficile over the Course of 10 Years in a Tertiary Care Hospital
Clinical Infectious Diseases, 10/16/09
Relevance Score: 67%
Clostridium difficile-related death rates in Texas 1999-2005
Journal of Infection, 10/06/09
Relevance Score: 67%
Bacteriophage-Mediated Toxin Gene Regulation in Clostridium difficile
Journal of Virology, 11/09/09
Relevance Score: 66%
Use of International Classification of Diseases, Ninth Revision, Clinical Modification Codes and Medication Use Data to Identify Nosocomial Clostridium difficile Infection
Infection Control and Hospital Epidemiology, 10/14/09
Relevance Score: 66%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Resorption and elimination kinetics of benzoic acid during chemical necrectomy in deep burns
Scandinavian Journal of Clinical and Laboratory Investigation, 12/19/09
Dienogest: a new therapeutic agent for the treatment of endometriosis *TEST*
Women's Health, 12/17/09
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
Investigational New Drugs, 12/17/09
Today in Gastroenterology...keeping you current
Receive free subspecialty "5-minute updates" via email
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
Investigational New Drugs, 12/17/09
Invasive front of colorectal cancer: Dynamic interface of pro-/anti-tumor factors
World Journal of Gastroenterology, 12/17/09
Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor
World Journal of Gastroenterology, 12/17/09
Today in Infectious Disease...keeping you current
Receive free subspecialty "5-minute updates" via email
Efficacy of Two Different Helicobacter pylori Eradication Regimens in Patients With Type 2 Diabetes and the Effect of Helicobacter pylori Eradication on Dyspeptic Symptoms in Patients With Diabetes: A Randomized Controlled Study
The American Journal of the Medical Sciences, 12/17/09
A Novel Influenza A (H1N1) Vaccine in Various Age Groups
New England Journal of Medicine, 12/17/09
The effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome - a randomized, double-blind, controlled study
Alimentary Pharmacology and Therapeutics, 12/17/09
Sponsor
Article Search
Sponsor
Sponsor